Kazia Therapeutics Limited Stock News

Kazia Therapeutics Ltd directors Dr James Garner and Iain Ross have shown their faith in the company's oncology-focused drug development strategy by acquiring shares on-market. Dr Garner, who is chie

Kazia Therapeutics Ltd has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies.  The oncology-focused d

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awarenes

SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its tw

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has made strong progress in the first half of 2021 with its oncology-focused drug development program, including the pipeline assets of paxalisib and EVT

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036. The on

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has teamed up with a medical college from Cornell University to launch a phase two clinical study investigating Kazia's investigational new drug paxalisi

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investig

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the fi

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the company's bio-tech strategy with on-market share purchases. Non-executive director Steven Coff

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it  "a vastly stronger and more substantial business", accordin

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial g

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of E